Beranda › Kolitis Ulseratif › Ohio
Uji klinis Kolitis Ulseratif di Ohio
26 studi untuk Kolitis Ulseratif mencari peserta di lokasi di Ohio.
Kota di Ohio
Teks studi resmi (Bahasa Inggris)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- dan 3 lainnya
Menerima pesertaFase 4
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06581328A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- University Hospitals Cleveland Medical Center /ID# 271831, Cleveland
Menerima pesertaFase 3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07071519A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- GCGA Physicians, LLC dba / Gastro Health Research, Cincinnati
- NexGen Research, Lima
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06598943Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Beavercreek
Menerima pesertaFase 1/2Sukarelawan sehat diterima
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06619990A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-025, Brunswick
- Site US-023, Dayton
- Site US-027, Westlake
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07845487A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaFase 3
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06663332A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Cleveland Clinic, Cleveland
Menerima pesertaFase 2/3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Dayton Gastroenterology, LLC, Dayton
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07186101LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Ohio State University, Hilliard
- DSI Research, LLC d/b/a ObjectiveHealth Clinical Research - Springboro, Springboro
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Gastro Intestinal Research Institute of Northern Ohio, LLC., Westlake
Menerima pesertaFase 4
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06095128Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
- Cleveland Clinic Foundation, Cleveland
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07513181A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- North Shore Gastroenterology Research - Site Number: 8400130, Westlake
Menerima pesertaFase 3
Usia 16 hingga 80 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Great Lakes Gastroenterology Research, LLC, Mentor
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07577856An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology & Hepatology Specialists, Inc. - Site Number: 8400139, Canton
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- dan 4 lainnya
Menerima pesertaFase 3
Usia 16 hingga 80 · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07184996Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07237516An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- University of Cincinnati College of Medicine, Cincinnati
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Menerima pesertaStudi observasional
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT06398626A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
- University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital, Cleveland
- University Hospitals Cleveland Medical Center, Cleveland
Menerima pesertaFase 2
Usia 12 hingga 17 · Semua jenis kelamin · Diperbarui 8 Jul 2026 · NCT05287126A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
Menerima pesertaFase 3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
Menerima pesertaFase 3
Usia 2 ke atas · Semua jenis kelamin · Diperbarui 7 Mei 2026 · NCT05442567ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
- Gastro Intestinal Research Institute of Northern Ohio,, Westlake
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 28 Apr 2026 · NCT06810518A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT07113522Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima peserta
Usia 13 hingga 17 · Semua jenis kelamin · Diperbarui 21 Nov 2025 · NCT07195123Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- University of Cincinnati, Cincinnati
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2025 · NCT06750731Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.